Wedbush Downgrades Aclaris Therapeutics to Neutral
Wedbush has downgraded Aclaris Therapeutics from Outperform to Neutral and reduced its price target for the company's stock.
Stocks · News reference
Shares of Cadeler A/S (NYSE: CDLR) surged in pre-market trading after reporting strong financial results for the first half of 2026. Revenue and profit increased significantly, and full-year guidance was maintained. Other stocks also moved in pre-market trading.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wedbush has downgraded Aclaris Therapeutics from Outperform to Neutral and reduced its price target for the company's stock.
J.P. Morgan analyst Priyanka Grover maintained a bullish rating on Kura Oncology and increased the price target from $30 to $32.
Generation Income Properties, Inc. provided a shareholder update detailing significant balance sheet improvements, including the completion of a $20 million redemption and a 73% reduction in redeemable non-controlling interests.
Envoy, a subsidiary of CID HoldCo, Inc. (Dot Ai), has launched an AI-powered vehicle damage detection system to automate fleet inspections and improve operational efficiency.
Expion Energy, Inc. announced its financial results for the third quarter of 2026 and highlighted the acquisition of a 3,000-acre oil and gas exploration prospect in Louisiana.
Filed: 2026-11-17 AccNo: 0001193125-26-464836 Size: 208 KB Item 7.01: Regulation FD Disclosure